Compare AbbVie Inc (ABBV) vs AGNC Investment Corp (AGNC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs AGNC Investment Corp — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while AGNC Investment Corp trades at $10.97 (market cap $12.76B). The key difference: AbbVie Inc is far larger — about 35.3× AGNC Investment Corp's market cap, and AGNC Investment Corp pays the higher dividend (12.95%). Which is the better fit depends on your goals.
| ABBV | AGNC | |
|---|---|---|
Market Cap | $449.91B | $12.76B |
Sector | Health | Financials |
52-Week High | $261.07 | $12.17 |
52-Week Low | $184.85 | $9.20 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 12.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
AGNC trades at $11.12, up 1.09% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $11.33. The stock shows strong profitability with a net income margin of 91.71% and ROE of 13.98%, though recent earnings have been mixed with a Q1 2026 beat but misses in prior quarters. Dividend payments of $0.12 per share continue regularly, supporting income-focused investors amid interest rate sensitivity concerns highlighted in recent news.
Outlook remains cautiously optimistic given analyst buy ratings (37.14%) and technical momentum, but risks include Federal Reserve policy shifts impacting mortgage-backed securities and earnings volatility. The stock's valuation at P/E 8.73 and P/B 1.26 offers relative value, though investors must monitor interest rate trends for dividend sustainability and book value stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →
